Hamburg sees Zicam action as "good outcome"
This article was originally published in The Tan Sheet
Executive Summary
FDA Commissioner Margaret Hamburg views the 2009 removal of intranasal zinc-containing Zicam products from store shelves as a good example of how the agency is more prevention-focused. After FDA learned of more than 130 cases of anosmia associated with the Matrixx Initiatives products, the agency "warned consumers not to use these products and the manufacturer removed them from the shelves a week later," Hamburg said Feb. 8 at the National Health Policy Conference in Washington. "This was a good outcome," she said, adding that in the past, FDA "found itself engaging in back-and-forths with companies and with lawyers while serious health and safety problems remained in limbo." Matrixx recently sued FDA for information about the call for removal of its top-selling Zicam products (1"The Tan Sheet" Feb. 1, 2010)
You may also be interested in...
Matrixx disputes Hamburg comments
FDA unfairly asked Matrixx Initiatives to recall its intranasal Zicam products with zinc, the firm argues. In response to Commissioner Margaret Hamburg's Feb. 8 comment that the agency's Zicam actions led to "a good outcome," Matrixx CEO William Hemelt says, "FDA made a major mistake that deprived the public of an effective and safe treatment for colds" (1"The Tan Sheet" Feb. 15, 2010, In Brief). Hemelt says in a Feb. 24 2letter the agency's reliance on previously rejected evidence linking zinc to anosmia and failure to engage with Matrixx "did a serious disservice to the truth, and also to due process." Hemelt added FDA's refusal to share documentation supporting its actions is inconsistent "with your attempts to restore confidence in the integrity of the agency.
Matrixx Initiatives Files Suit Against FDA On Unanswered FOIA Grounds
Matrixx Initiatives is suing FDA for the release of information related to the recall of its Zicam zinc-containing intranasal cold remedy products from the market
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.